[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin reported an option exercise and share sale. On April 14, 2026, she exercised employee stock options covering 15,250 shares of common stock at exercise prices of $22.40, $8.93, and $20.46 per share. She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After these transactions, she directly held 42,353 shares of Travere Therapeutics common stock.

Insights

Equity compensation & insider trading analyst

Pre-planned option exercise and partial sale; sizable but routine.

The filing shows Sandra Calvin, SVP and Chief Accounting Officer at Travere Therapeutics, exercising stock options for 15,250 shares at strike prices of $22.40, $8.93, and $20.46. These are standard employee stock options with multi-year vesting schedules.

She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction. A footnote states the sale was executed under a written Rule 10b5-1 plan adopted on June 10, 2025, indicating the trade was pre-planned rather than opportunistic.

Following the transactions, Calvin directly holds 42,353 common shares. The combination of option exercise and partial share sale appears to be typical liquidity management associated with equity compensation, with no additional signals on company fundamentals in this disclosure.

Insider Trade Summary 10b5-1

Net Seller: 21,977 shares ($902,595)

Net Sell 7 txns

Insider Calvin Sandra

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 21,977 shs ($903K)

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	2,500	$0.00	--
Exercise	Employee stock option (right to buy)	6,250	$0.00	--
Exercise	Employee stock option (right to buy)	6,500	$0.00	--
Exercise	Common Stock	2,500	$22.40	$56K
Exercise	Common Stock	6,250	$8.93	$56K
Exercise	Common Stock	6,500	$20.46	$133K
Sale	Common Stock	21,977	$41.07	$903K

Holdings After Transaction: Employee stock option (right to buy) — 5,000 shares (Direct); Common Stock — 51,580 shares (Direct)

Footnotes (1)

1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calvin Sandra

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		M		2,500	A	$22.4	51,580	D
Common Stock	04/14/2026		M		6,250	A	$8.93	57,830	D
Common Stock	04/14/2026		M		6,500	A	$20.46	64,330	D
Common Stock	04/14/2026		S(1)		21,977	D	$41.07	42,353	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$22.4	04/14/2026		M			2,500	(2)	01/31/2033	Common Stock	2,500	$0	5,000	D
Employee stock option (right to buy)	$8.93	04/14/2026		M			6,250	(3)	01/31/2034	Common Stock	6,250	$0	12,500	D
Employee stock option (right to buy)	$20.46	04/14/2026		M			6,500	(4)	01/31/2035	Common Stock	6,500	$0	19,500	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

3. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

4. One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Travere Therapeutics (TVTX) executive Sandra Calvin report in this Form 4?

Sandra Calvin reported exercising employee stock options and selling shares of Travere Therapeutics common stock. She exercised options for 15,250 shares, then sold 21,977 shares in an open-market transaction, and ended the day holding 42,353 shares directly.

How many Travere Therapeutics (TVTX) shares did Sandra Calvin sell and at what price?

Sandra Calvin sold 21,977 shares of Travere Therapeutics common stock at $41.07 per share. The transaction was reported as an open-market sale and executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted in June 2025.

How many Travere Therapeutics (TVTX) shares did Sandra Calvin acquire through option exercises?

She acquired 15,250 Travere Therapeutics common shares by exercising employee stock options. The options were exercised at strike prices of $22.40, $8.93, and $20.46 per share, reflecting previously granted equity awards with multi-year vesting schedules.

What are Sandra Calvin’s Travere Therapeutics (TVTX) holdings after these transactions?

After the reported transactions, Sandra Calvin directly holds 42,353 shares of Travere Therapeutics common stock. This figure reflects her position following the option exercises for 15,250 shares and the subsequent sale of 21,977 shares on April 14, 2026.

Was the Travere Therapeutics (TVTX) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the 21,977-share sale was made under a written trading plan adopted on June 10, 2025 that meets Rule 10b5-1(c) requirements. Such plans pre-schedule trades, making their timing less indicative of the insider’s short-term outlook.